After the successful completion of the first project phase, the BMBF has granted a second round of funding for the m4 project of apceth within the framework of the Leading-Edge Cluster m4 – Personalized Medicine. In this project, an innovative therapeutic against advanced and/or metastatic cancers is developed, which consists of mofified adult mesenchymal stem cells. The cell product is named Agenmestencel-T and will be custom-made for each patient. A biomarker strategy is to assess which patients will benefit most from the innovative therapeutic.
To the press release from apceth